Pharmaceutical composition for preventing and treating intestinal type radiation sickness

A radiation sickness and composition technology, applied in the field of biomedicine, can solve the problem of intestinal radiation sickness that has not yet been seen in combination with FTY720 and linaclotide

Active Publication Date: 2019-03-19
ACADEMY OF MILITARY MEDICAL SCI
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, there is no report on the combination of FTY720 and linaclotide used in the prevention and treatment of intestinal radiation sickness

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing and treating intestinal type radiation sickness
  • Pharmaceutical composition for preventing and treating intestinal type radiation sickness
  • Pharmaceutical composition for preventing and treating intestinal type radiation sickness

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] Example 1 Establishment of mouse intestinal type radiation sickness model

[0066] 1. Selection and feeding of experimental animals

[0067] 50 male C57 / BL6 mice aged 6-8 weeks, weighing 20-25g. All mice were raised in a specific pathogen-free (SPF) grade animal room in a standardized animal center, fed with standard pellet feed, free to drink and eat, room temperature was (22±2)°C, and relative humidity was 40%-60%. After 7 days of adaptive feeding, they were used for experiments.

[0068] 2. The principle of making the model

[0069] Large doses of X-rays irradiating the abdomen of mice can cause gastrointestinal tissue damage and cause intestinal radiation sickness.

[0070] 3. Model preparation and standards

[0071] Shield the other parts of the mouse with a barrier device (such as a lead plate), expose the abdomen, give the mouse abdominal X-ray irradiation (25Gy), and detect a sharp decrease in the number of white blood cells in the blood image, which means t...

Embodiment 2

[0072] Example 2 The therapeutic effect of FTY720 and linaclotide on experimental animals

[0073]The model prepared above was used as the experimental object to verify the therapeutic effect of FTY720 and linaclotide on it.

[0074] 1. Administration method and specific route

[0075] Immediately after successful modeling, oral administration on an empty stomach, dose: FTY720, 1 mg / kg / time; linaclotide, 50 μg / kg / time, once a day for 10 days. The time interval between the two administrations is about 30 minutes.

[0076] 2. Section HE staining

[0077] 2.1 Materials

[0078] Mice were sacrificed and intestinal tissue removed.

[0079] 2.2 Slicing and staining

[0080] 2.3 Results

[0081] The result is as figure 2 As shown, severe intestinal tissue damage was seen in the untreated group, including epithelial-basement membrane separation in the intestinal mucosa, crypt cell edema, hyperemia, necrosis, and exposed villi. In the FTY720(F) treatment group and the linaclot...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition for preventing and treating enter radiation diseases. The pharmaceutical composition comprises FTY720 and linaclotide. Experiments prove that the synergistic effect can be achieved due to combined application of the two medicines of the FTY720 and the linaclotide, and intestinal tissue injury repair after radiation is obviously enhanced. The research result provides a specific medicine for treating the enter radiation diseases clinically, and the specific medicine has wide application prospect.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to a pharmaceutical composition for preventing and treating intestinal radiation sickness. The pharmaceutical composition includes FTY720 and linaclotide. technical background [0002] Due to nuclear leakage (such as the Chernobyl nuclear accident and the Fukushima nuclear accident), the leakage of large doses of nuclear substances caused damage to the human body caused by radiation, which became radiation sickness. Radiation sickness can be divided into acute, subacute and chronic according to the exposure time. When the radiation dose exceeds 15Gy, multiple organs in the whole body (such as bone marrow, gastrointestinal tract, etc.) will be severely damaged, especially the intestinal tissue, so it is called intestinal radiation sickness. Intestinal form of acute radiation sickness is a very serious acute radiation sickness characterized by gastrointestinal symptoms such as ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/10A61P1/00A61K31/137
CPCA61K31/137A61K38/10A61K2300/00
Inventor 陈国江韩根成黎燕冯健男沈倍奋吕忠霖
Owner ACADEMY OF MILITARY MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap